Data support Avandia (rosiglitazone maleate) cardiovascular safety profile

Data support Avandia (rosiglitazone maleate) cardiovascular safety profile

Issued: Friday 9 July 2010, London UK

The U.S. Food and Drug Administration (FDA) today posted a comprehensive review conducted by GlaxoSmithKline (GSK) of the cardiovascular safety data on Avandia® (rosiglitazone maleate). GSK's review supports the overall positive benefit-risk profile of rosiglitazone as an important medicine for patients with type 2 diabetes.

The data in GSK's review come from meta-analyses, observational studies and large controlled clinical trials that have become available since July 2007, when the FDA convened advisory committees to review the efficacy and safety of rosiglitazone. The FDA's Endocrinologic and Metabolic Drugs, and the Drug Safety and Risk Management Advisory Committees will review these data at a meeting on 13-14 July 2010.

"Since 2007 we have seen results from six controlled clinical trials looking at the cardiovascular safety of Avandia and together they show that this medicine does not increase the overall risk of heart attack, stroke or death," said Dr. Murray Stewart, Vice President for Clinical Development at GSK. "We also know that Avandia lowers glucose levels in both the short- and long-term and is the only oral anti-diabetic medicine that has been shown to sustain blood sugar control for up to five years.[1] We look forward to presenting these data and participating in a rigorous scientific discussion with the advisory committees."

About nine percent of adults in the U.S. have type 2 diabetes, which has increased from five percent in 1997 (Ref CDC website).  Type 2 diabetes is characterised by high blood sugar levels and it represents a major health risk with complications that can include blindness, kidney failure, amputations, heart attack and stroke.

A three-page executive summary of GSK's briefing document for the FDA meeting and a copy of the complete briefing document is posted on the FDA's website.

[1] Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427-2443.

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com or the Avandia resource centre.

 
 
GlaxoSmithKline Enquiries:
 
 
 
UK Media enquiries:
 Philip Thomson
Claire Brough
Stephen Rea
Alexandra Harrison
Jo Revill
 (020) 8047 5502
(020) 8047 5502
(020) 8047 5502
(020) 8047 5502
(020) 8047 5502
 
 
  
  
 
US Media enquiries:
 Nancy Pekarek
Mary Anne Rhyne
Kevin Colgan
Sarah Alspach
 (919) 483 2839
(919) 483 2839
(919) 483 2839
(919) 483 2839
 
 
 
 
 
European Analyst/
Investor enquiries:
 David Mawdsley
Sally Ferguson
Gary Davies
 (020) 8047 5564
(020) 8047 5543
(020) 8047 5503
 
 
 
 
 
US Analyst/
Investor enquiries:
 Tom Curry
Jen Hill Baxter
 (215) 751 5419
(215) 751 7002
 

 

Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

New York's Covaxx has signed on with three South American nations to provide 140 million doses of its early-stage COVID-19 vaccine.

To get the COVID-19 vaccine out quickly, Pfizer has been running rehearsals at distribution sites, creating "growing confidence," U.S. officials said.